These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36720562)

  • 41. Nine-year trend of oral anticoagulant use in patients with embolic stroke due to nonvalvular atrial fibrillation.
    Asahina C; Umetani K; Sano K; Yano T; Nakano S
    J Arrhythm; 2020 Oct; 36(5):883-889. PubMed ID: 33024465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.
    Cullell N; Carrera C; Muiño E; Torres N; Krupinski J; Fernandez-Cadenas I
    Oncotarget; 2018 Jun; 9(49):29238-29258. PubMed ID: 30018749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation.
    Alalwan AA; Voils SA; Hartzema AG
    Am J Health Syst Pharm; 2017 Aug; 74(16):1237-1244. PubMed ID: 28652320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
    Kim H; Lee YS; Kim TH; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Shim J; Uhm JS; Park HW; Choi EK; Kim JB; Kim C; Kim J; Joung B
    Korean J Intern Med; 2020 Jan; 35(1):99-108. PubMed ID: 31014064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve.
    Cao Y; Zheng Y; Li S; Liu F; Xue Z; Yin K; Luo J
    Front Cardiovasc Med; 2022; 9():899906. PubMed ID: 35783817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of direct oral anticoagulant for acute major cerebral artery occlusion in cardioembolic stroke/transient ischemic attack patients with non-valvular atrial fibrillation.
    Tomari S; Arima J; Yoshida T; Yamashita H; Sata R; Hamada R; Kanda N; Takashima H
    J Neurol Sci; 2019 Jul; 402():162-166. PubMed ID: 31152970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study.
    Bartoli-Abdou JK; Patel JP; Vadher B; Brown A; Roberts LN; Patel RK; Arya R; Auyeung V
    Thromb Res; 2021 Dec; 208():162-169. PubMed ID: 34801919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data.
    Kefale AT; Peterson GM; Bezabhe WM; Bereznicki LR
    Expert Rev Clin Pharmacol; 2022 Mar; 15(3):351-357. PubMed ID: 35184624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort.
    Rodriguez-Bernal CL; Peiró S; Hurtado I; García-Sempere A; Sanfélix-Gimeno G
    J Manag Care Spec Pharm; 2018 May; 24(5):440-448. PubMed ID: 29694286
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anticoagulant treatment in elderly patients with atrial fibrillation: position paper].
    Hanon O; Jeandel C; Jouanny P; Paccalin M; Puisieux F; Krolak-Salmon P; Berrut G
    Geriatr Psychol Neuropsychiatr Vieil; 2019 Dec; 17(4):341-355. PubMed ID: 31848123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
    Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
    Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study.
    Halvorsen S; Smith JA; Söderdahl F; Thuresson M; Solli O; Ulvestad M; Jonasson C
    BMC Prim Care; 2022 Aug; 23(1):214. PubMed ID: 36008778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation.
    Bezabhe WM; Bereznicki LR; Radford J; Wimmer BC; Curtain C; Salahudeen MS; Peterson GM
    Front Pharmacol; 2021; 12():586370. PubMed ID: 33867975
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.
    Ramakumar V; Benz AP; Karthikeyan G
    Indian Heart J; 2021; 73(2):244-248. PubMed ID: 33865530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation.
    Arbel A; Abu-Ful Z; Preis M; Cohen S; Saliba W
    Br J Clin Pharmacol; 2021 Dec; 87(12):4747-4755. PubMed ID: 33982796
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.
    Olsen AS; McGettigan P; Gerds TA; Fosbøl EL; Olesen JB; Sindet-Pedersen C; Staerk L; Lock Hansen M; Pallisgaard JL; Køber L; Torp-Pedersen C; Gislason GH; Lamberts M
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):292-300. PubMed ID: 31742339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.